Trial Profile

A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients With Recurrent Ovarian Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Olaparib (Primary) ; Sargramostim (Primary) ; UV 1 (Primary)
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Proof of concept; Therapeutic Use
Acronyms DOVACC

Most Recent Events

26 Jun 2026 Primary endpoint (Progression-free survival (PFS)) has not been met, according to Zelluna ASA media release.
26 Jun 2026 Results presented in the Zelluna ASA media release.
27 Feb 2026 Planned primary completion date changed from 31 Dec 2026 to 1 May 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com